secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001193125-25-051072
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam prices $500M underwritten offering of common stock and pre-funded warrants
-------------------------------------------------------------------------------

- Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.
- Gross proceeds ~$500.0M; net proceeds after discounts and expenses ~$469.7M.
- Use of proceeds: platform technology, R&D for BEAM-101, BEAM-302 pivotal trial, ESCAPE conditioning trial, general corporate.
- Closing expected March 11, 2025; J.P. Morgan, Jefferies, Cantor, Citigroup, Wells Fargo as joint bookrunners.
- Pre-funded warrants exercisable immediately at $0.01 per share, with cashless exercise and beneficial ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525051072/0001193125-25-051072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525051072/d930164d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-051072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer